From Survival to Execution: Rani Therapeutics’ High-Risk, High-Reward Pivot with Transformative Chugai Deal
Overview
Rani Therapeutics is a clinical-stage biotherapeutics company poised to revolutionize the delivery of injectable biologics with its proprietary RaniPill® technology, converting painful injections into patient-friendly pills. With the October 2025 Chugai partnership and a large private financing, Rani moved from existential risk and financial distress to a platform-validated, well-funded enterprise with operations extended into 2028. The market has shifted its focus from the company’s survival to its capability to execute: the path forward now hinges on successful delivery of partnership milestones and leveraging high-status validation for further strategic deals, despite recent shareholder dilution.